⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Supplementary Figure S2 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

Katsushige Kawase Shusuke Kawashima Tatsuya Nishi Takashi Inozume Takao Morinaga Masahito Kawazu Toyoyuki Hanazawa Yosuke Togashi

View Full Paper

Ask AI

Bookmark

Share

Key Points

Finding indicates reduced cd155 expression improves antitumor immunity, addressing immunotherapy resistance.
Key evidence shows that manipulating the PI3K/Akt signaling pathway affects cd155 levels significantly.
Observational analysis exploring the relationship between cd155 expression and cancer immunotherapy outcomes.
Implications suggest targeting the PI3K/Akt pathway may enhance cancer treatment effectiveness, given initial findings.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals how reduced cd155 expression enhances antitumor immunity, highlighting PI3K/Akt involvement.

Abstract

Additional data on the impact of reduced CD155 expression on antitumor immunity

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kawase et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21ad2 https://doi.org/10.1158/2326-6066.30255055

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025
2Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025
3Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025
4Supplementary Figure 3 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025
5Supplementary Figure S5 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy2025